SLS vs SNSE

SELLAS Life Sciences Group, Inc vs Sensei Biotherapeutics, Inc. — Valuation Comparison 2026

SLS

Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc
Quality
4.1
out of 10
Value Trap
18
SAFE
Price
$9.31
Last close
Models
7/13
Active
VS

SNSE

Pharmaceutical Preparations
Sensei Biotherapeutics, Inc.
Quality
3.7
out of 10
Value Trap
36
LOW
Price
$21.14
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType SLS Fair ValueSLS Upside SNSE Fair ValueSNSE Upside
Bayesian DCF Intrinsic $2.61 -72.0% $66.45 +214.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.15 -98.4% $1.33 -95.1%
Dynamic NAV Asset-Based $0.65 -93.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLS vs SNSE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLS vs SNSE — Which Stock Is More Undervalued?

SLS scores higher with a 4.1/10 quality rating vs SNSE's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SELLAS Life Sciences Group, Inc (SLS) and Sensei Biotherapeutics, Inc. (SNSE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLS currently trades at $9.31 with a QOC of 4.1/10, while SNSE trades at $21.14 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).